Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Jiménez Jorge, Silvia ^a,b   de Mateo, Salvador ^a,b   Delgado Sanz, Concha ^a   Pozo, Francisco ^c   Casas, Inmaculada ^c   Garcia Cenoz, Manuel ^b,d   Castilla, Jesús ^b,d   Pérez, Esteban ^e   Gallardo, Virtudes ^e   Rodriguez, Carolina ^f   Vega, Tomás ^f   Quiñones, Carmen ^g   Martínez, Eva ^g   Vanrell, Juana María ^h   Giménez, Jaume ^h   Castrillejo, Daniel ⁱ   Serrano, María del Carmen ^j   Ramos, Julián Mauro ^j   Larrauri, Amparo ^a,b  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^e Servicio de Epidemiología Y Salud Laboral   (Spain)

^f Prevención Y Educación de la Salud   (Spain)

^g Registro de Cáncer Servicio de Epidemiología Dirección General de Salud Pública y Consumo Conselleria de Salut Família i Benestar Social   (Spain)

^h Servicio de Epidemiologia   (Spain)

ⁱ Hospital Comarcal de Melilla   (Spain)

^j Unidad Medicalizada de Emergencia   (Spain)

more..

Author keywords

Case control studies; Discordant strain; Influenza; Sentinel networks; Vaccine effectiveness; Waning immunity

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; INFANT; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; SCHOOL CHILD; SEASON; SMOKING HABIT; SPAIN; VIRUS STRAIN;

ADOLESCENT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PHYLOGENY; SEASONS; SENTINEL SURVEILLANCE; SPAIN; VACCINATION; YOUNG ADULT;

EID: 84884317970     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-441     Document Type: Article

References (46)

1. World Health Organization Meeting of the strategic advisory group of experts on immunization, April 2012 - conclusions and recommendations. World Health Organization. 2012, 87(21):201-216. http://www.who.int/wer/2012/wer8721.pdf, World Health Organization.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2011, 12:36-44.
3. Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, Lopalco PL, Weber JT, Johansen K, Dematte L, Salmaso S, Stefanoff P, Greco D, Dorleans F, Polkowska A, O'Flanagan D. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill 2010, 15(44):1-10. http://www.eurosurveillance.org/images/dynamic/EE/V15N44/art19700.pdf.
4. Ministry of Health and Social Policy S Prevención de la gripe. Recomendaciones de vacunación antigripal [Influenza prevention. Recommendations for influenza vaccination] 2011, Spain: Ministry of Health and Social Policy, http://www.msps.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/home.htm, Ministry of Health and Social Policy S.
5. Savulescu C, Valenciano M, de Mateo S, Larrauri A, . the cycEVA Study Team Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network-pilot case-control studies using different control groups, 2008-2009 season, Spain. Vaccine 2010, 28(16):2903-2907. 10.1016/j.vaccine.2010.01.054, 20153351, the cycEVA Study Team.
6. Savulescu C, Jimenez-Jorge S, De Mateo S, Pozo F, Casas I, Perez-Brena P, Galmes A, Vanrell JM, Rodriguez C, Vega T, Martinez A, Torner N, Ramos JM, Serrano MC, Castilla J, Garcia CM, Altzibar JM, Arteagoitia JM, Quiñones C, Perucha M, Larrauri A, . on behalf of the Spanish Influenza Surveillance System Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case controls studies, Spain, season 2009-2010. BMC Public Health 2011, 11:899-907. 10.1186/1471-2458-11-899, 3262832, 22129083, on behalf of the Spanish Influenza Surveillance System.
7. Jimenez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, Larrauri A. Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 2012, 30:3595-3602. 10.1016/j.vaccine.2012.03.048, 22472792.
8. Larrauri A, Savulescu C, Jimenez-Jorge S, Perez-Brena P, Pozo F, Casas I, Ledesma J, de Mateo S. Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain. Gac Sanit 2011, 25(1):23-28. 10.1016/j.gaceta.2010.06.010, 21334788.
9. Valenciano M, Ciancio B, Moren A. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA member states. Euro Surveill 2008, 13(43):1-8. http://www.eurosurveillance.org/images/dynamic/EE/V13N43/art19015.pdf.
10. Kissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12. Euro Surveill 2012, 17(15):1-7. http://www.eurosurveillance.org/images/dynamic/EE/V17N15/art20146.pdf.
11. Jimenez-Jorge S, de Mateo S, Pozo F, Casas I, Garcia CM, Castilla J, Gallardo V, Perez E, Vega T, Rodriguez C, Quinones C, Martinez E, Gimenez J, Vanrell J, Castrillejo D, Serrano M, Ramos J, Larrauri A. Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012. Euro Surveill 2012, 17(12):1-6. http://www.eurosurveillance.org/images/dynamic/EE/V17N12/art20129.pdf.
12. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen J, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jimenez-Jorge S, Horvath J, Daviaud I, Guiomar R, Necula G, Bella A, Donnell O, Gluchowska M, Ciancio B, Nicoll A, Moren A. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013, 18(5). http://www.eurosurveillance.org/images/dynamic/EE/V18N05/art20390.pdf.
13. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson C, Robertson C, Cottrell S, Smyth B, Zambon M, Moore C, Fleming D, Watson J. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013, 18(5). http://www.eurosurveillance.org/images/dynamic/EE/V18N05/art20389.pdf.
14. Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia CM, Guevara M, Moran J, Irisarri F, Arriazu M, Albeniz E, Ezpeleta C, Barricarte A. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013, 18(5). http://www.eurosurveillance.org/images/dynamic/EE/V18N05/art20388.pdf.
15. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J Infect Dis 2008, 197(4):490-502. 10.1086/524146, 18275271.
16. European Centre for Disease Prevention and Control Protocol for case-control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. Technical document 2009, 1-27. Stockholm, Sweden: European Centre for Disease Prevention and Control, European Centre for Disease Prevention and Control.
17. Rothman KJ, Greenland S, Lash TL, Rothman KJ, Greenland S, Lash TL. editors.Modern epidemiology 2008, 128-47. Philadelphia: Lippincott-Raven, 3, Volume 9. Validity in epidemiologic studies.
18. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013, 31(17):2165-2168. 10.1016/j.vaccine.2013.02.053, 23499601.
19. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of seasonal influenza vaccine. Vaccine 2013, 31(30):3104-3109. 10.1016/j.vaccine.2013.04.026, 23624093.
20. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, Kwindt TL, Chan T, Bastien N, Charest H, Li Y. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009, 199(2):168-179. 10.1086/595862, 19086914.
21. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ, Miller E, Zambon M. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health 2010, 64(12):1062-1067. 10.1136/jech.2009.093450, 19910645.
22. Kelly H, Valenciano M. Estimating the effect of influenza vaccines. Lancet Infect Dis 2012, 12(1):5-6. http://ac.els-cdn.com/S1473309911702894/1-s2.0-S1473309911702894-main.pdf?_tid=3b3875ecef41e3c86ee2403d8cfab8b2&acdnat=1343039760_9612548832981a739951cf59b3638fd9, 10.1016/S1473-3099(11)70289-4, 22032845.
23. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 2010, 28(46):7381-7388. http://www.sciencedirect.com/science/article/pii/S0264410X10013186, 10.1016/j.vaccine.2010.09.010, 20851086.
24. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199(2):159-67. 10.1086/595861, 19086915.
25. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, Sebastian R, Chong M, Tam T, De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007, 25(15):2842-2851. http://www.sciencedirect.com/science/article/pii/S0264410X06011054, 10.1016/j.vaccine.2006.10.002, 17081662.
26. Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I. Estimation of influenza vaccine effectiveness from routine surveillance data. PLoS ONE 2009, 4(3):e5079. 10.1371/journal.pone.0005079, 2658741, 19333374.
27. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, Orenstein WA. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 2007, 36(3):623-631. http://ije.oxfordjournals.org/content/36/3/623.full.pdf+html, 10.1093/ije/dym021, 17403908.
28. Puig-Barbera J. 2010-2011 influenza seasonal vaccine, preliminary mid-season effectiveness estimates: reason for concern, confounding or are we following the right track?. Euro Surveill 2011, 16(11). http://www.eurosurveillance.org/images/dynamic/EE/V16N11/art19821.pdf.
29. World Health Organization Review of the 2011-2012 winter influenza season, northern hemisphere. Weekly epidemiological record 2012, 24(87):233-240. http://www.who.int/wer/2012/wer8724.pdf, World Health Organization.
30. Centro Nacional de Epidemiología.Instituto de Salud Carlos II Informes anuales de gripe. Vigilancia de la Gripe en España. Sistema centinela 2012, Centro Nacional de Epidemiología.Instituto de Salud Carlos III, http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/gripe.shtml. Accessed: 10 May 2013, Centro Nacional de Epidemiología.Instituto de Salud Carlos II.
31. European Centre for Disease Control and Prevention (ECDC) European Centre for Disease Control and Prevention (ECDC), Technical document. Influenza virus characterisation - Summary Europe 2012, 1. Stockholm, Sweden: European Centre for Disease Prevention and Control, European Centre for Disease Control and Prevention (ECDC).
32. Fielding JE, Grant KA, Tran T, Kelly HA. Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. Euro Surveill 2012, 17(11):1-5. http://www.eurosurveillance.org/images/dynamic/EE/V17N11/art20115.pdf.
33. Fielding JE, Grant KA, Papadakis G, Kelly HA. Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008. BMC Infect Dis 2011, 11:170-178. 10.1186/1471-2334-11-170, 3131256, 21669006.
34. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25(39-40):6852-6862.
35. Centers for Disease Control and Prevention Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 2008, 57(15):393-398. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5715a1.htm, Centers for Disease Control and Prevention.
36. World Health Organization Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season [Internet] 2012, 1-16. World Health Organization, http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf, World Health Organization.
37. Gross PA, Russo C, Teplitzky M, Dran S, Cataruozolo P, Munk G. Time to peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 1996, 3(3):361-362. 170348, 8705685.
38. Brydak LB, Machala M, Mysliwska J, Mysliwski A, Trzonkowski P. Immune response to influenza vaccination in an elderly population. J Clin Immunol 2003, 23(3):214-222. 10.1023/A:1023314029788, 12797543.
39. Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, Sambhara S. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis 2012, 3(1):68-90. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320806/pdf/ad-3-1-68.pdf, 3320806, 22500272.
40. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jimenez-Jorge S, Savulescu C, Ciancio B, Moren A. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS ONE 2011, 6(11):e27622. 10.1371/journal.pone.0027622, 3216983, 22110695.
41. Beyer WE, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989, 7(5):385-394. 10.1016/0264-410X(89)90150-3, 2683459.
42. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994, 12(13):1185-1189. 10.1016/0264-410X(94)90241-0, 7839722.
43. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Thomas D, Sebastianpillai P, Ellis J, Carman W, Wreghitt T, Zambon M, Watson J. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill 2011, 16(6):1-6. http://www.eurosurveillance.org/images/dynamic/EE/V16N06/art19791.pdf.
44. Castilla J, Moran J, Martinez-Artola V, Reina G, Martinez-Baz I, Garcia CM, Alvarez N, Irisarri F, Arriazu M, Elia F, Salcedo E. Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro Surveill 2011, 16(7):1-6. http://www.eurosurveillance.org/images/dynamic/EE/V16N07/art19799.pdf.
45. Savulescu C, Jimenez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, Larrauri A. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro Surveill 2011, 16(11):1-6. http://www.eurosurveillance.org/images/dynamic/EE/V16N11/art19820.pdf.
46. Nicoll A, Sprenger M. Low effectiveness undermines promotion of seasonal influenza vaccine. Lancet Infect Dis 2013, 13(1):7-9. 10.1016/S1473-3099(12)70313-4, 23257219.